59 related articles for article (PubMed ID: 52365)
1. Metabolism of a prednisolone compound in human under normal and pathological conditions.
Fehér T; Koref O; Tankó A; Bodrogi L; Poteczin E
Arzneimittelforschung; 1975 Aug; 25(8):1314-7. PubMed ID: 52365
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone metabolism in normal subjects and in patients with liver cirrhosis.
Váradi A; Fehér T; Bodrogi L; Koref O
Arzneimittelforschung; 1977; 27(8):1618-20. PubMed ID: 578759
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroid-induced changes in urea metabolism in patients with hepatocellular disease.
Jones EA; Cain GD; Dickinson G
Gastroenterology; 1972 Apr; 62(4):612-7. PubMed ID: 5020873
[No Abstract] [Full Text] [Related]
4. [Pharmacokinetics and pharmacodynamics of prednisolone following extremely high dosage as prednisolone hemisuccinate].
Rohdewald VP; Rehder J; Möllmann H; Barth J; Derendorf H
Arzneimittelforschung; 1987 Feb; 37(2):194-8. PubMed ID: 3580023
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolism of theophylline in patients with liver diseases.
Staib AH; Schuppan D; Lissner R; Zilly W; von Bomhard G; Richter E
Int J Clin Pharmacol Ther Toxicol; 1980 Nov; 18(11):500-2. PubMed ID: 7203726
[TBL] [Abstract][Full Text] [Related]
6. The effects of age and liver disease on the disposition and elimination of diazepam in adult man.
Klotz U; Avant GR; Hoyumpa A; Schenker S; Wilkinson GR
J Clin Invest; 1975 Feb; 55(2):347-59. PubMed ID: 1127104
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of picumast dihydrochloride in patients with liver cirrhosis.
Neugebauer G; Raedsch R; Stiehl A; Kaufmann B; Besenfelder E; Neubert P; Walter-Sack I
Arzneimittelforschung; 1989 Oct; 39(10A):1343-7. PubMed ID: 2576360
[TBL] [Abstract][Full Text] [Related]
8. [Metabolism of hexobarbital in patients with acute hepatitis and cirrhosis (author's transl)].
Richter E; Gallenkamp H; Keller B; Brachtel D; Zilly W; Breimer DD
Z Gastroenterol; 1977 Jun; 15(6):381-8. PubMed ID: 888488
[TBL] [Abstract][Full Text] [Related]
9. Biotransformation of perchloroethene: dose-dependent excretion of trichloroacetic acid, dichloroacetic acid, and N-acetyl-S-(trichlorovinyl)-L-cysteine in rats and humans after inhalation.
Völkel W; Friedewald M; Lederer E; Pähler A; Parker J; Dekant W
Toxicol Appl Pharmacol; 1998 Nov; 153(1):20-7. PubMed ID: 9875296
[TBL] [Abstract][Full Text] [Related]
10. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
11. Half-life time or clearance of indocyanine green in patients with liver disease.
Gilmore IT; Marigold JH; Thompson RP
Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
[TBL] [Abstract][Full Text] [Related]
12. The effect of liver disease in man on the disposition of phenobarbital.
Alvin J; McHorse T; Hoyumpa A; Bush MT; Schenker S
J Pharmacol Exp Ther; 1975 Jan; 192(1):224-35. PubMed ID: 235636
[TBL] [Abstract][Full Text] [Related]
13. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
Kirch W; Köhler H; Berggren G; Braun W
Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
[TBL] [Abstract][Full Text] [Related]
14. Impaired elimination of meperidine in patients with liver disease.
McHorse TS; Klotz U; Wilkinson G; Schenker S
Trans Assoc Am Physicians; 1974; 87():281-7. PubMed ID: 4456737
[No Abstract] [Full Text] [Related]
15. Urinary 6 beta-hydroxyprednisolone excretion indicates enhanced prednisolone catabolism.
Frey FJ; Frey BM
J Lab Clin Med; 1983 Apr; 101(4):593-604. PubMed ID: 6833830
[TBL] [Abstract][Full Text] [Related]
16. [Clinico-prognostic significance of plasma cortisol half-life(after intravenous administration ) during acute and chronic hepatic diseases].
Del Prete S; Malacco E; Bonzi G; Natelli A; Roncoroni S; Jalanbo H
Minerva Med; 1975 Mar; 66(22):1051-7. PubMed ID: 1124151
[TBL] [Abstract][Full Text] [Related]
17. Urinary excretion of prednisolone following intravenous administration in humans.
al-Habet SM; Rogers HJ
J Clin Pharmacol; 1989 Oct; 29(10):922-7. PubMed ID: 2592584
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration.
Täuber U; Haack D; Nieuweboer B; Kloss G; Vecsei P; Wendt H
Int J Clin Pharmacol Ther Toxicol; 1984 Jan; 22(1):48-55. PubMed ID: 6698661
[TBL] [Abstract][Full Text] [Related]
19. [Phenazon metabolism in children with liver diseases].
Orzechowska-Juzwenko K; Rabenda C; Wiela-Hojeńska A; Kubicz Z; Saraczyńska E; Rudkowski Z; Drabik E
Pol Tyg Lek; 1992 Mar 16-30; 47(11-13):265-7. PubMed ID: 1437728
[No Abstract] [Full Text] [Related]
20. Investigation of biotransformation capacity in patients with chronic liver diseases by pharmacokinetic methods: experimental trials.
Horváth T; Past T; Tatai Z; Pár A; Kádas I; Tapsonyi Z; Jávor T
Pol J Pharmacol Pharm; 1984; 36(4):361-71. PubMed ID: 6396596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
